Manoj K. Jain, MD

home / authors / manoj-k-jain-md

Articles

Dr. Jain on the Use of Diagnostic Tracers in Prostate Cancer

Dr. Jain on the Use of Diagnostic Tracers in Prostate Cancer

Manoj K. Jain, MD
May 19th 2020

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Read More

Dr. Jain on the Use of Diagnostic Tracers in Prostate Cancer

Dr. Jain on the Use of Diagnostic Tracers in Prostate Cancer

Manoj K. Jain, MD
May 18th 2020

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Read More

Dr. Jain on Radioligand Therapy in Prostate Cancer

Dr. Jain on Radioligand Therapy in Prostate Cancer

Manoj K. Jain, MD
September 5th 2019

Manoj K. Jain, MD, discusses the use of radioligand therapy in prostate cancer.

Read More

Dr. Jain on the Indications for PET Imaging in Prostate Cancer

Dr. Jain on the Indications for PET Imaging in Prostate Cancer

Manoj K. Jain, MD
August 20th 2019

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses the indications for PET imaging in prostate cancer.

Read More

Dr. Jain on Novel Imaging Technologies for Prostate Cancer

Dr. Jain on Novel Imaging Technologies for Prostate Cancer

Manoj K. Jain, MD
August 13th 2019

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses new imaging modalities to detect disease in patients with prostate cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need